Yescarta genetically modified autologous T cells for infusion Images
Generic Name: axicabtagene ciloleucel
This medication has been identified as Yescarta genetically modified autologous T cells for infusion. It is supplied by Kite Pharma, Inc.
Yescarta is used in the treatment of Diffuse Large B-Cell Lymphoma; B-Cell Lymphoma; Follicular Lymphoma and belongs to the drug class miscellaneous antineoplastics. Yescarta genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Yescarta
- Generic Name
- axicabtagene ciloleucel
- Strength
- genetically modified autologous T cells for infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Kite Pharma, Inc.
- National Drug Code (NDC)
- 71287-0119
See also:
More about Yescarta (axicabtagene ciloleucel)
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.